Drugs / SLS-005
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05332678 | Mar → Apr 2023 | Alzheimer disease | Seelos Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT05490563 | Jun 2022 → Nov 2023 | Machado-Joseph disease | Seelos Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLS-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05332678 ↗ |
| Known as | trehalose | “Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly” NCT04297683 ↗1“SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion)” NCT05490563 ↗ |
| Route | Other | “Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly” NCT04297683 ↗ |